(Reuters) – The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.
The vaccine, which like their other COVID shots will also be sold under brand Comirnaty, has been approved for use in individuals aged 6 months and above, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
MHRA’s approval for the shot follows the European regulator’s clearance last week.
Besides Pfizer-BioNTech, other vaccine makers Moderna and Novavax have also created so-called monovalent versions of their shots that target only the XBB.1.5 subvariant of the virus.
While the U.S. expects to deploy all three vaccines in the fall season, the UK plans to deploy the mRNA vaccines by Pfizer-BioNTech and Moderna for the autumn immunization campaign.
XBB.1.5 was the most dominant variant globally earlier this year, which led the regulators, including the U.S. Food and Drug Administration, to select it as the target for coronavirus vaccines.
(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar and Shinjini Ganguli)
Source link : https://www.medscape.com/s/viewarticle/996101?src=rss
Publish date : 2023-09-06 13:10:20
Copyright for syndicated content belongs to the linked Source.